# Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

> **NCT05304585** · PHASE3 · RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 205 (estimated)

## Conditions studied

- Embryonal Rhabdomyosarcoma
- Fusion-Negative Alveolar Rhabdomyosarcoma
- Spindle Cell/Sclerosing Rhabdomyosarcoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Dactinomycin
- **PROCEDURE:** Magnetic Resonance Elastography
- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Radiation Therapy
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT05304585
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-04
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304585, "Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05304585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*